TY - JOUR

T1 - Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up

T2 - Results from a nationwide observational study in people with type 2 diabetes

AU - Vilsboll, Tina

AU - Lindahl, Caroline O.

AU - Nielsen, Nick F. F.

AU - Tikkanen, Christian K. K.

PY - 2023

Y1 - 2023

N2 - Aim To investigate the impact of treatment with once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for up to 2 years in people with type 2 diabetes (T2D) managed in routine clinical practice.Materials and methods The study was based on data from national registries. People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included. Data were collected at baseline and after 180, 360, 540 and 720 days of treatment (all timepoints +/- 90 days).Results In total, 9284 people redeemed at least one semaglutide prescription (intention-to-treat) and 4132 people redeemed semaglutide continuously (on-treatment). For the on-treatment cohort, the median (interquartile range) age was 62.0 (16.0) years, diabetes duration was 10.8 (8.7) years, and glycated haemoglobin (HbA1c) level was 62.0 (18.0) mmol/mol at baseline. A subset of the on-treatment cohort, comprising 2676 people, had HbA1c measurements at baseline and at least once during 720 days. The mean (95% confidence interval) changes in HbA1c after 720 days were -12.6 (-13.6; -11.6) mmol/mol (P < 0.001) for GLP-1RA-naive people, and -5.6 (-6.2; -5.0) mmol/mol (P < 0.001) for GLP-1RA-experienced people. Similarly, 55% of GLP-1RA-naive people and 43% of GLP-1RA-experienced people reached a HbA1c target of

AB - Aim To investigate the impact of treatment with once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for up to 2 years in people with type 2 diabetes (T2D) managed in routine clinical practice.Materials and methods The study was based on data from national registries. People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included. Data were collected at baseline and after 180, 360, 540 and 720 days of treatment (all timepoints +/- 90 days).Results In total, 9284 people redeemed at least one semaglutide prescription (intention-to-treat) and 4132 people redeemed semaglutide continuously (on-treatment). For the on-treatment cohort, the median (interquartile range) age was 62.0 (16.0) years, diabetes duration was 10.8 (8.7) years, and glycated haemoglobin (HbA1c) level was 62.0 (18.0) mmol/mol at baseline. A subset of the on-treatment cohort, comprising 2676 people, had HbA1c measurements at baseline and at least once during 720 days. The mean (95% confidence interval) changes in HbA1c after 720 days were -12.6 (-13.6; -11.6) mmol/mol (P < 0.001) for GLP-1RA-naive people, and -5.6 (-6.2; -5.0) mmol/mol (P < 0.001) for GLP-1RA-experienced people. Similarly, 55% of GLP-1RA-naive people and 43% of GLP-1RA-experienced people reached a HbA1c target of

KW - database research

KW - GLP-1

KW - glycaemic control

KW - real-world evidence

KW - semaglutide

KW - type 2 diabetes

KW - THERAPEUTIC INERTIA

KW - HYPERGLYCEMIA

KW - MANAGEMENT

KW - UPDATE

KW - SYSTEM

KW - MG

U2 - 10.1111/dom.15031

DO - 10.1111/dom.15031

M3 - Journal article

C2 - 36809678

VL - 25

SP - 1740

EP - 1749

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -